Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Juni 2020

Planlagt Fastgjort Låst Flyttet Genmab
2.0k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • SolsenS Offline
    SolsenS Offline
    Solsen
    wrote on sidst redigeret af
    #1698

    Vores venner Horizon glimrer i disse dage

    1 Reply Last reply
    0
    • SolsenS Offline
      SolsenS Offline
      Solsen
      wrote on sidst redigeret af
      #1699

      Jeg ser ingen problemer i at den løber over $100 inden for relativ kort tid. Og så tror jeg slet ikke man medregner Teprotumumab udenfor US.

      1 Reply Last reply
      0
      • SolsenS Offline
        SolsenS Offline
        Solsen
        wrote on sidst redigeret af
        #1700

        Bispecifics er in og nu med CD28 https://finance.yahoo.com/news/publication-highlights-preclinical-research-showing-180000874.html

        1 Reply Last reply
        0
        • Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktør
          wrote on sidst redigeret af
          #1701

          I 2006 kørte et forsøg med CD28 fuldstændigt af sporet med patienter der røg på intensiv og vist nok flere døde. Man er heldigvis kommet videre siden.

          1 Reply Last reply
          0
          • Helge_LarsenPI-redaktørH Offline
            Helge_LarsenPI-redaktørH Offline
            Helge_LarsenPI-redaktør
            wrote on sidst redigeret af
            #1702

            Har tjekket historien. Ingen døde, men oplevede voldsomme bivirkninger som var livstruende.

            1 Reply Last reply
            0
            • Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktør
              wrote on sidst redigeret af
              #1703

              Forsøget medførte at Torben Plesner og Genmab var ekstremt forsigtige med doseringen da man startede forsøg op med daratumumab.

              1 Reply Last reply
              0
              • B Offline
                B Offline
                bibob
                wrote on sidst redigeret af
                #1704

                God morgen 🙂

                1 Reply Last reply
                0
                • B Offline
                  B Offline
                  bibob
                  wrote on sidst redigeret af
                  #1705

                  Community advice : SQ formulation of Daratumumab. ( transscript ) https://www.onclive.com/insights/daratumumab-subcutaneous-formulation-for-treatment-of-mm?eKey=amFuYm9ydXAxOTc4QGdtYWlsLmNvbQ==

                  1 Reply Last reply
                  0
                  • T Offline
                    T Offline
                    transalp
                    wrote on sidst redigeret af
                    #1706

                    Go morgen .. 🙂

                    1 Reply Last reply
                    0
                    • B Offline
                      B Offline
                      bibob
                      wrote on sidst redigeret af
                      #1707

                      GMAB US lukkede i + 10 ( +0,30 % ). 🙂

                      1 Reply Last reply
                      0
                      • J Offline
                        J Offline
                        JKY_VH
                        wrote on sidst redigeret af
                        #1708

                        God morgen;-)

                        1 Reply Last reply
                        0
                        • Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktør
                          wrote on sidst redigeret af
                          #1709

                          God morgen. 🙂

                          1 Reply Last reply
                          0
                          • Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktør
                            wrote on sidst redigeret af
                            #1710

                            Nikkei 225 i Tokyo faller 1,33 prosent
                            Kospi i Seoul faller 1,70 prosent
                            Singapore-børsen er ned 1,17 prosent
                            ASX 200 i Sydney faller 1,63 prosent

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #1711

                              Nogen der kender denne Halozymes klon?

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #1712

                                Just a moment...

                                favicon

                                (www.firstwordpharma.com)

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #1713

                                  @Solsen / Helge , Sanofi is already working on a trispecific CD3, CD28, and CD38

                                  1 Reply Last reply
                                  0
                                  • J Offline
                                    J Offline
                                    JKY_VH
                                    wrote on sidst redigeret af
                                    #1714

                                    Credit Suisse sænker kursmål til DKK 2.235 fra DKK 2.300 og ændrer anbefaling til ’Neutral’ fra ’Outperform’

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #1715

                                      well, ok, but UBS Reiterates Buy Rating on Genmab A/S (GEN:DC) (GMAB) 😉

                                      1 Reply Last reply
                                      0
                                      • G Offline
                                        G Offline
                                        GeorgeBest
                                        wrote on sidst redigeret af
                                        #1716

                                        ** Credit Suisse downgrades Danish pharmaceutical company Genmab GMAB.CO to "neutral" from "outperform" after it had found a material error in the PharmaValues net present value (NPV) calculation for the company
                                        ** Due to the error, the value of cancer drug Darzalex and chronic lymphocytic leukemia antibody ofatumumab royalties to Genmab were overstated, the brokerage says
                                        ** CS says its revised Genmab PharmaValues Equity NPV is DKK 1,800/share, reduced from DKK2,300/share seen previously

                                        1 Reply Last reply
                                        0
                                        • G Offline
                                          G Offline
                                          GeorgeBest
                                          wrote on sidst redigeret af
                                          #1717

                                          ** However, the error did not impact the broker's revenue or earnings model assumptions
                                          ** CS cuts it target price to DKK 2,235 from DKK 2,300 using the average Biotech and Specialty Pharma EV/NPV premium of 30%
                                          ** Following significant stock performance in H1 2020, the broker sees more limited near-term upside
                                          ** It still sees ofatumumab sales by partner Novartis NOVN.S as underappreciated
                                          ** It expects more modest further catalysts in H2 2020 following the positive AbbVie's ABBV.N oncology pa

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger